Here we present a protocol using nerve conduction studies and ultrasound to screen potential axonal degeneration associated with carpal tunnel syndrome. The criteria for differentiation are established. Compared to conventional approaches, this method is noninvasive, convenient, and efficient, with an overall satisfactory accuracy, sensitivity, and specificity.
Axonal degeneration, indicative of surgical decompression, may coexist in carpal tunnel syndrome (CTS) as the disease progresses. However, the current diagnostic and severity gradation system cannot clearly indicate its coexistence, resulting in confusion of appropriate treatment prescription. There are also constraints in conventional methods for differentiation as well. This study aims at introducing an innovative, efficient, and quick screening protocol to differentiate axonal degeneration associated with CTS, using ultrasound and nerve conduction studies (NCS). It starts by using NCS to perform orthodromic stimulation at the wrist, to obtain the sensory conduction of the median and the ulnar nerves respectively. Meanwhile, the motor conduction of the median nerve is collected by stimulating the palm, wrist, and elbow, followed by the stimulation of the ulnar nerve at the wrist, below and above the elbow. Then, an ultrasound assessment is performed, using a linear array transducer, with cross-sectional area (CSA) and perimeter (P) at the wrist and at the one-third distal forearm calipered. Ratios (R-CSA, R-P) and changes from wrist to one-third distal forearm (ΔCSA and ΔP) are calculated according to a standard format. Potential axonal degeneration coexisting in CTS will be screened according to the criteria of NCS and cut-off values of ultrasound measurements established in a previous study. In terms of its noninvasiveness, low cost, convenience, and efficiency, it is easy to apply ultrasound complimentarily in clinical practice to prescreen patients with potential coexisting axonal degeneration. Nevertheless, the ultrasonographic imaging cannot directly reflect axonal degeneration. It still relies on conventional but invasive methods such as electromyography (EMG) and biopsy for confirmation if needed.
CTS is pathologically a disorder with segmental demyelination, whereas secondary axonal degeneration, which is indicative of surgical decompression, may coexist as the disease progresses1. However, the current diagnostic and severity gradation scale (from mild to very severe grade) for CTS cannot clearly indicate any coexistence of axonal degeneration, resulting in confusion when choosing the appropriate treatment. Conventional methods for confirming axonal degeneration, such as needle EMG and nerve biopsy, can be sensitive and accurate, but they are both restricted in the clinical practice due to their invasiveness2.
To overcome these shortcomings, ultrasound has been introduced for assisting diagnosing3,4,5 and grading of the severity of CTS6,7,8. Also, previous study successfully identified its cut-off values for discriminating axonal degeneration associated with CTS, with overall satisfactory sensitivity and specificity9. This study aims at introducing this efficient and noninvasive protocol to the practice in the clinical context. The rationale of this protocol is to combine the neurophysiological and structural information provided by NCS and ultrasounds to indicate the pathological progress1,10. It is assumed to be more accurate to describe the pathological progress than the current severity gradation system, helping clinicians to better figure out a plan of care. Compared to other conventional neuroimaging techniques such as diffusion tensor imaging (DTI), this evidence-based approach can be more easily applied in clinical settings with lower costs11.
All the procedures have been approved by the University of Hong Kong/Hospital authorities Hong Kong West Institutional Review Board (HKU/HA HKW IRB, Ref. Number: UW17-129).
This protocol is applicable to patients who demonstrated clinical symptoms such as numbness, tingling, or pain over the median nerve-innervated area of the hand, with a positive outcome in Tinel's sign and Phalen's test. Those subjects with comorbidities, such as diabetes mellitus, cancer, rheumatoid arthritis, and other peripheral neuropathies, are not eligible for this protocol.
1. Measurement of the Nerve Conduction Studies
2. Measurements Using Ultrasound
3. Screening of Potential Coexisting Axonal Degeneration in Carpal Tunnel Syndrome
As was described in Table 1, associated axonal degeneration has been primarily screened out should the subject fulfill the criteria of NCS as follows: (1) the sensory conduction velocity of the median nerve is less than 42m/s and/or (2) the distal sensory latency is more than 4.6 ms or the distal motor latency is more than 3.2 ms; (3) the SNAP amplitude at the wrist is less than 10 µV with the CMAP amplitude drop being no more than 20%. Those with temporal dispersion (a CMAP amplitude drop of >20%) and/or conduction block (a CMAP amplitude drop of >50%) will be excluded. Regarding the criteria of the NCS parameters, which include conduction velocity, distal latency, SNAP amplitude, exclusion of conduction block12 and temporal dispersion13, they were all set based on previously well-established references and our laboratory practical standard.
Then, the measured readings of the ultrasound parameters will also be taken into account. The CSA is the coronal size of the nerve measured by tracing the hyperechoic epineurium, while the P is the circumference of the traced hyperechoic epineurium. R-CSA/R-P is calculated by the CSA/P measured at the carpal inlet divided by that measured in the one-third distal forearm. ΔCSA/ΔP is the change of CSA/P from the wrist to the one-third distal forearm. The cut-off values and the sensitivity, specificity, and accuracy of the ultrasound parameters were determined by plotting receiver operative characteristics (ROC) curves, which were identified in a previous study9. The positive predictive value and negative predictive value are also displayed in Table 1. Those patients with any ultrasound parameter value(s) above the correspondent cut-off value(s) will be considered as suffering from the potential coexistence of axonal degeneration. Alternatively, the ultrasound readings can also be considered as indicators of potential axonal degeneration, should the subject not fulfill the NCS criteria in Table 1.
A group of 80 subjects who fulfilled the NCS criteria in Table 1 was enrolled via convenience sampling to examine the effectiveness of the protocol. They were assigned to group A (demyelination only, n1 = 45) and group B (associated axonal degeneration, n2 = 35), based on the NCS criteria in Table 1. By between group comparison, significant differences were found in NCS and ultrasound measurements (Table 2). The results indicate this protocol can be effective in screening axonal degeneration associated with CTS.
On the other hand, another group of 46 subjects (group C), who did not fulfill the NCS criteria in Table 1, were enrolled with ultrasound measurements generated descriptively. Based on the ultrasound performance, the enrolled subjects were all potentially associated with coexisting axonal degeneration (Table 2).
Figure 1: Measurement of the conduction in the sensory median and ulnar nerve. Please click here to view a larger version of this figure.
Figure 2: Measurement of the conduction in the motor median nerve. Please click here to view a larger version of this figure.
Figure 3: Measurement of the conduction in the motor ulnar nerve. Please click here to view a larger version of this figure.
Figure 4: Measurement by ultrasound. Please click here to view a larger version of this figure.
Figure 5: Measurement of the inlet of the carpal tunnel and its ultrasound imaging. Please click here to view a larger version of this figure.
Figure 6: Measurement of the one-third distal forearm and its ultrasound imaging. Please click here to view a larger version of this figure.
Criteria for determining axonal degeneration according to measurement of nerve conduction studies | ||||||
(1) Conduction velocity of the median sensory nerve <42m/s (less than 75% of the lower limit of normal, and/or (2) Distal sensory latency > 4.6 ms or distal motor latency >3.2 ms (more than 130% of the upper limit of normal) (3) Sensory nerve action potential (SNAP) amplitude at the wrist <10 μV with compound motor action potential (CMAP) amplitude drop ≤ 20%; (4) Exclude conditions of CMAP amplitude drop >20%, which may be indicative of temporal dispersion and/or conduction block (CMAP amplitude drop >50%) |
||||||
Criteria for determining axonal degeneration according to ultrasound measurement | ||||||
Cut-off values | Accuracy | Sensitivity (%) | Specificity (%) | Positive Predicative Value (%) | Negative Predicative Value (%) | |
(1) CSA(mm2) | 12 | 0.71 | 80% | 48.90% | 75.90% | 45.10% |
(2) P(mm) | 16.27 | 0.748 | 88.60% | 51.10% | 85.20% | 41.50% |
(3) R-CSA | 1.85 | 0.725 | 85.70% | 48.90% | 81.50% | 43.40% |
(4) R-P | 1.48 | 0.676 | 80% | 40% | 72% | 49.10% |
(5) ΔCSA(mm2) | 6.98 | 0.758 | 77.10% | 62.20% | 77.80% | 38.60% |
(6) ΔP(mm) | 5.77 | 0.717 | 80% | 46.70% | 80.60% | 36.40% |
Table 1: Criteria for determining axonal degeneration associated with carpal tunnel syndrome by nerve conduction studies and ultrasound. Remarks: R-CSA or R-P = CSA or P at the wrist/CSA or P at the one-third distal forearm; ΔCSA or ΔP = CSA or P at the wrist minus CSA or P at the one-third distal forearm.
Group A(n1=45) | Group B(n2=35) | Group C(n3=46) | |
Demographics | |||
Gender# | |||
Female | 35 | 31 | 45 |
Male | 10 | 4 | 1 |
Age | 58.58(8.44) | 65.4(7.96)* | 58.98(7.08) |
Handedness | |||
Right | 23 | 20 | 23 |
Left | 22 | 15 | 23 |
Severity grade* | |||
Mild | 20 | 9 | 29 |
Mild to moderate | 8 | 0 | 4 |
Moderate | 14 | 7 | 7 |
Moderate to severe | 1 | 6 | 5 |
Severe | 2 | 13 | 1 |
Nerve Conduction Studies | |||
Median Motor Nerve | Group A | Group B | Group C |
Palmar DML | 1.99(.27) | 2.1(.21) | 1.92(.23) |
Palmar CMAP | 8.46(2.51) | 7.68(2.26) | 8.91(2.4) |
Wrist ML | 4.74(1.13) | 6.25(1.62)* | 4.5(1.5) |
Wrist CMAP | 8.32(2.5) | 7(2.0)# | 8.12(2.72) |
Wrist MCV | 27.28(7.46) | 20.4(6.17)* | 33.32(11.15) |
Median Sensory nerve | Group A | Group B | Group C |
DSL | 3.22(.43) | 3.61(.46)* | 2.82(.68) |
SNAP | 12.82(4.41) | 6.21(2.23)* | 13.77(4.93) |
SCV | 36.39(6.3) | 33.74(4.23) | 46.02(6.26) |
Ultrasound Measurements | |||
Ultrasound parameters | Group A | Group B | Group C |
CSA(mm2) | 12.5(4.0) | 16.54(6.81)* | 14.18(3.55) |
P(mm) | 16.71(2.86) | 19.64(4.08)* | 18.31(2.5) |
R-CSA | 2.03(0.67) | 2.79(1.01)* | 2.69(.74) |
R-P | 1.63(.39) | 1.9((0.47)* | 1.84(.26) |
ΔCSA(mm2) | 6.17(3.76) | 10.4(6.13)* | 8.73(2.97) |
ΔP(mm) | 6.22(3.28) | 9.08(4.04)* | 8.25(1.99) |
*<0.01;#<0.05; | |||
DML(ms): distal motor latency, CMAP(mV): compound motor action potential, ML(ms): Motor latency; MCV(m/s): motor conduction velocity; MCV: motor conduction velocity; DSL(ms): distal sensory latency; SNAP(μV): sensory nerve action potential; SCV(m/s): sensory conduction velocity ;W-CSA(mm2): wrist cross-sectional area, W-P (mm): wrist perimeter; R-CSA: ratio of cross sectional area of wrist over one third distal forearm, R-P: ratio of perimeter of wrist over one third distal forearm, DCSA (mm2): changes of cross-sectional area from wrist to one third distal forearm, DP (mm): changes of perimeter from wrist to one third distal forearm |
Table 2: Demographics and performance of nerve conduction studies and ultrasound measurements of the enrolled subjects.
It is challenging to set up a universal standard for the measurement of NCS due to the influence of demographic and physical factors such as age, gender, ethnicities, and body weight, etc.14. Regarding SNAP amplitude, there is a difference between the orthodromic (the direction of currency runs proximally toward the body) and antidromic (the direction of currency runs distally away from the body) technique, as the SNAP amplitude measured by the orthodromic method is smaller than the antidromic method15. In our laboratory, orthodromic stimulation has generally been applied clinically such that we set 10 µV as the cut-off value of determining axonal damage. A higher SNAP amplitude is required should the antidromic technique be applied.
On the other hand, for the measurement of ultrasound, we took the inlet of the carpal tunnel and the one-third distal forearm as the bony markers for measurement. These measurement sites were consistent with previous studies, bearing a comparatively higher accuracy for diagnosing the disease3,4,8,16,17,18, which may also increase the accuracy of discrimination consequently, increase the accuracy of discrimination. In addition, one of the most innovative aspects of this method is that the cut-off values of the ultrasound parameters can take a complementary role when the electric signal of NCS is absent or did not fulfill the NCS criteria for differentiation as they displayed overall satisfactory sensitivity and specificity in a previous study9. Compared to previous cut-off values identified for severity gradation8,19,20, these cut-off values are believed to be more indicative clinically for treatment prescription as they can reflect pathological progress beyond the conventional severity grade.
Nevertheless, there are also constraints using this method. First, the specificity is inferior to the sensitivity in this protocol, as can be seen from the ultrasound findings among subjects in group C, all of which were considered with potential associated axonal degeneration based on the ultrasound cut-off readings. This can be explained as we have not yet established a concrete assessment package to confirm axonal degeneration based on various ultrasound parameters. Besides, the nature of ultrasound imaging also cannot directly display axonal degeneration. It still relies on the golden standard test to confirm axonal degeneration. Also, there is yet no universal agreement upon NCS criteria for discriminating axonal degeneration9. Further studies are required to examine its reliability by comparison with the golden standard test. Despite these limitations, we still propose this method as an efficient screening approach as it can quickly inform clinicians at an early stage in a noninvasive manner, thus avoiding deterioration.
Bearing overall satisfactory accuracy, sensitivity, and specificity, the combinative use of ultrasound and NCS cannot only compensate for technical pitfalls of NCS (absent signals, etc.) by providing anatomical and structural information, but also it can disclose or identify the pathological progress lying underneath. This method can be applied easily in routine clinical practice for the initial screening of the potential coexistence of axonal degeneration associated with CTS. A more refined plan of care can be attainable using this method.
The authors have nothing to disclose.
Mr. Xue Deng, Dr. Yong Hu, and Dr. Ip Wing-Yuk were dedicated to the concept of the study design, subject recruitment, and draft and revision of the manuscript. Ms. Lai-Heung Phoebe Chau and Ms. Suk-Yee Chiu were dedicated to subject liaison, data collection, and the manipulation of NCS. Dr. Kwok-Pui Leung was dedicated to the electrophysiological diagnosis, clinical guidance, and the manipulation of the ultrasounds.